DMYTRENKO, I. V.; MINCHENKO, Zh. M; FEDORENKO, V. V.; DYAGIL, I. S. SIGNIFICANCE OF ADDITIONAL CHROMOSOMAL ABNORMALITIES FOR THE OUTCOMES AFTER THE SECOND LINE NILOTINIB THERAPY IN THE CHRONIC MYELOID LEUKEMIA PATIENTS. International Journal of Medicine and Medical Research, [S. l.], v. 5, n. 1, p. 33–39, 2019. DOI: 10.11603/ijmmr.2413-6077.2019.1.10305. Disponível em: https://ojs.tdmu.edu.ua/index.php/ijmr/article/view/10305. Acesso em: 18 mar. 2026.